Open Access

Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)

  • Authors:
    • Yan-Jun Zhong
    • Li-Hua Shao
    • Yan Li
  • View Affiliations

  • Published online on: December 28, 2012     https://doi.org/10.3892/ijo.2012.1754
  • Pages: 373-383
  • Copyright: © Zhong et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Doxorubicin (DOX) is one of the most effective cytotoxic anticancer drugs used for the treatment of hematological malignancies, as well as a broad range of solid tumors. However, the clinical applications of this drug have long been limited due to its severe dose‑dependent toxicities. Therefore, DOX derivatives and analogs have been developed to address this issue. A type of DOX prodrug, cleaved by cathepsin B (Cat B), which is highly upregulated in malignant tumors and premalignant lesions, has been developed to achieve a higher DOX concentration in tumor tissue and a lower concentration in normal tissue, so as to enhance the efficacy and reduce toxicity to normal cells. In this review, we focused on Cat B-cleavable DOX prodrugs and discussed the efficacy of these prodrugs, demonstrated by preclinical and clinical developments.
View Figures
View References

Related Articles

Journal Cover

February 2013
Volume 42 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhong, Y., Shao, L., & Li, Y. (2013). Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). International Journal of Oncology, 42, 373-383. https://doi.org/10.3892/ijo.2012.1754
MLA
Zhong, Y., Shao, L., Li, Y."Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)". International Journal of Oncology 42.2 (2013): 373-383.
Chicago
Zhong, Y., Shao, L., Li, Y."Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)". International Journal of Oncology 42, no. 2 (2013): 373-383. https://doi.org/10.3892/ijo.2012.1754